Lansing, MI-based superconducting accelerator technology firm Niowave has inked a long-term agreement to supply Novartis with actinium-225 (Ac-225).
The agreement will provide Novartis with a scalable supply of the medical isotope to support its growing portfolio of radioligand therapies (RLT). RLTs use a targeting component with a radioisotope to selectively target and destroy cancer cells, Niowave said. Financial terms of the agreement were not disclosed…